GO:0070915 lysophosphatidic acid receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070915 (lysophosphatidic acid receptor activity) is a molecular function defined as combining with lysophosphatidic acid (LPA) and transmitting the signal across the membrane by activating an associated G-protein.
• LPA receptors are G-protein-coupled receptors (GPCRs) that mediate diverse cellular responses including proliferation, migration, survival, and contraction.
• The LPA receptor family includes LPA1 (LPAR1), LPA2 (LPAR2), LPA3 (LPAR3), LPA4 (LPAR4), LPA5 (LPAR5), and LPA6 (LPAR6), each with distinct tissue distribution and downstream signaling.
• Dysregulated LPA signaling is implicated in pulmonary fibrosis, hypertrophic cardiomyopathy, neuropathic pain, nonalcoholic steatohepatitis (NASH), and ferroptosis regulation [1,2,5,6,8].
• Pharmacological inhibition of LPA1 (e.g., BMS-986278, EPGN2154) shows therapeutic potential in preclinical models of fibrosis and NASH [2,8].
• CRISPR-based knockout, point mutation, knock-in, and overexpression models are essential for dissecting LPA receptor function and validating drug targets.
Description
Lysophosphatidic acid (LPA) is a bioactive phospholipid that exerts pleiotropic effects on cell physiology by activating specific G-protein-coupled receptors (GPCRs). The Gene Ontology (GO) term GO:0070915, lysophosphatidic acid receptor activity, captures the molecular function of these receptors: binding LPA and transmitting the signal across the membrane by activating an associated G-protein. This activity is fundamental to understanding how extracellular lipid signals are converted into intracellular responses, influencing processes such as cell proliferation, migration, survival, and differentiation. Researchers study LPA receptors because they are implicated in a wide range of pathological conditions, including fibrosis, cardiovascular disease, pain, and metabolic disorders [1,2,5,6,8]. The LPA receptor family comprises at least six members (LPA1–LPA6) with distinct expression patterns and signaling properties, making them attractive targets for therapeutic intervention. This article provides a comprehensive overview of the mechanism, key genes, disease relevance, and research methodologies associated with GO:0070915, with a focus on CRISPR-based approaches for functional validation.
lysophosphatidic acid receptor activity At A Glance
| GO ID | GO:0070915 |
|---|---|
| GO term | lysophosphatidic acid receptor activity |
| Ontology | molecular_function |
| Synonym | LPA receptor activity |
| Definition | Combining with the phospholipid derivative lysophosphatidic acid, and transmitting the signal across the membrane by activating an associated G-protein. |
| Major function | Binding LPA and activating G-protein-mediated signaling |
| Receptor family | G-protein-coupled receptors (GPCRs) |
| Key subtypes | LPA1 (LPAR1), LPA2 (LPAR2), LPA3 (LPAR3), LPA4 (LPAR4), LPA5 (LPAR5), LPA6 (LPAR6) |
| Associated diseases | Pulmonary fibrosis, hypertrophic cardiomyopathy, neuropathic pain, NASH, ferroptosis-related conditions |
What Is GO:0070915?
In our own words, GO:0070915 describes the molecular function of a receptor that specifically binds lysophosphatidic acid (LPA), a phospholipid derivative, and upon binding, triggers a conformational change that activates an associated heterotrimeric G-protein. This activation initiates intracellular signaling cascades, thereby transmitting the signal across the plasma membrane. This activity is characteristic of the LPA receptor family of GPCRs.
Why Is lysophosphatidic acid receptor activity Important in Cell Biology?
Lysophosphatidic acid receptor activity is critically important because it mediates the cellular response to LPA, a lipid mediator involved in numerous physiological and pathological processes. Dysregulated LPA signaling contributes to fibrosis, cardiovascular remodeling, pain sensitization, and metabolic dysfunction, making these receptors prime targets for drug development [1,2,5,6,8]. Understanding the precise molecular mechanisms and identifying the specific receptors involved in disease contexts can guide the design of selective antagonists or agonists. Moreover, CRISPR-based genome editing enables causal validation of receptor function, accelerating translational research.
• LPA receptors regulate cell proliferation, migration, and survival, impacting tissue homeostasis and repair.
• LPA1 (LPAR1) is a validated target for pulmonary fibrosis; antagonists like BMS-986278 are in clinical development [1,2].
• Ablation of LPA1 attenuates hypertrophic cardiomyopathy in mouse models, highlighting its role in cardiac remodeling.
• LPA5 (LPAR5) in the insular cortex is a potential analgesic target for neuropathic pain.
• LPA1 antagonism causes regression of NASH in preclinical models, linking LPA signaling to metabolic liver disease.
• LPA3 (LPAR3) activation is involved in the regulation of ferroptosis, a form of regulated cell death.
• Crosstalk between cannabinoid receptor 2 and LPA5 modulates signaling, expanding the complexity of LPA receptor biology.
• LPA receptor modulators are being developed for therapeutic use, underscoring the druggability of this receptor family.
Molecular Mechanism of lysophosphatidic acid receptor activity
LPA Binding and Receptor Activation
In simple terms: LPA binds to the receptor like a key in a lock, causing the receptor to change shape and become active.
Lysophosphatidic acid (LPA) binds to the extracellular domain of LPA receptors, which are G-protein-coupled receptors (GPCRs). This binding induces a conformational change in the receptor, enabling it to act as a guanine nucleotide exchange factor (GEF) for the associated heterotrimeric G-protein.
G-Protein Activation and Signal Transduction
In simple terms: The activated receptor turns on a G-protein, which then passes the signal to other proteins inside the cell.
Upon LPA binding, the receptor catalyzes the exchange of GDP for GTP on the G-alpha subunit of the G-protein. The GTP-bound G-alpha subunit dissociates from the G-beta/gamma dimer, and both components go on to modulate downstream effectors such as adenylyl cyclase, phospholipase C, and ion channels, thereby transmitting the signal across the membrane.
Receptor Subtypes and Signaling Diversity
In simple terms: Different LPA receptors can trigger different internal signals, allowing LPA to have many effects.
The LPA receptor family includes LPA1–LPA6, which couple to different G-proteins (G12/13, Gi, Gq, etc.) and exhibit distinct tissue expression patterns. This diversity enables LPA to elicit context-dependent cellular responses, such as proliferation, migration, or contraction.
Regulation and Desensitization
In simple terms: After signaling, the receptor can be turned off to prevent overstimulation.
Like many GPCRs, LPA receptors undergo phosphorylation by G-protein-coupled receptor kinases (GRKs) followed by beta-arrestin recruitment, leading to desensitization and internalization. This regulatory mechanism controls the duration and intensity of LPA signaling.
Key Genes Involved in GO:0070915 lysophosphatidic acid receptor activity
The following genes encode the LPA receptors and related signaling components that mediate lysophosphatidic acid receptor activity.
| Gene | Major Role | Research Relevance |
|---|---|---|
| LPAR1 | Encodes LPA1 receptor; couples to G12/13, Gi, Gq | Target in pulmonary fibrosis, hypertrophic cardiomyopathy, NASH [1,2,5,8] |
| LPAR2 | Encodes LPA2 receptor; couples to Gi, Gq | Implicated in cell survival and migration |
| LPAR3 | Encodes LPA3 receptor; couples to Gi, Gq | Involved in ferroptosis regulation |
| LPAR4 | Encodes LPA4 receptor; couples to Gs, G12/13 | Roles in development and vascular biology |
| LPAR5 | Encodes LPA5 receptor; couples to G12/13, Gq | Analgesic target in neuropathic pain; crosstalk with CB2 [3,6] |
| LPAR6 | Encodes LPA6 receptor; couples to G12/13 | Hair growth and immune regulation |
| GNA12 | G-alpha 12 subunit; mediates LPA-induced Rho activation | Downstream effector of LPA receptors |
| GNA13 | G-alpha 13 subunit; mediates LPA-induced Rho activation | Downstream effector of LPA receptors |
| GNAI1 | G-alpha i1 subunit; inhibits adenylyl cyclase | Downstream effector of LPA receptors |
| GNAQ | G-alpha q subunit; activates phospholipase C | Downstream effector of LPA receptors |
| RHOA | Small GTPase; regulates cytoskeleton | Mediates LPA-induced cell migration and contraction |
| ROCK1 | Rho-associated kinase; downstream of RhoA | Involved in LPA-induced stress fiber formation |
| PLCB1 | Phospholipase C beta 1; generates IP3 and DAG | Mediates LPA-induced calcium signaling |
| AKT1 | Serine/threonine kinase; promotes survival | Downstream of LPA-induced PI3K signaling |
| MAPK1 | Mitogen-activated protein kinase 1; regulates proliferation | Downstream of LPA-induced Ras-MAPK pathway |
| CTNNB1 | Beta-catenin; mediates Wnt signaling crosstalk | Potential crosstalk with LPA signaling |
How Is lysophosphatidic acid receptor activity Regulated?
LPA receptor activity is regulated at multiple levels. Receptor expression is controlled transcriptionally and post-transcriptionally, influencing cellular responsiveness to LPA. At the protein level, agonist-induced phosphorylation by GRKs and subsequent beta-arrestin binding lead to desensitization and internalization, terminating the signal. Additionally, LPA can be produced and degraded by enzymes such as autotaxin (ENPP2) and lipid phosphate phosphatases, which regulate the availability of the ligand. Crosstalk with other GPCRs, such as cannabinoid receptor 2, can modulate LPA5 signaling. These regulatory mechanisms ensure tight control of LPA-mediated responses.
lysophosphatidic acid receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LPAR1 | Pulmonary fibrosis, NASH, hypertrophic cardiomyopathy | Lpar1 knockout mouse; LPA1 antagonist treatment [1,2,5,8] |
| LPAR3 | Ferroptosis regulation | Lpar3 knockout or overexpression cell lines |
| LPAR5 | Neuropathic pain | Lpar5 knockout mouse; insular cortex-specific knockdown |
| LPAR2 | Cell survival and migration | Lpar2 knockout cell lines |
| LPAR6 | Hair growth, immune regulation | Lpar6 knockout mouse |
Pulmonary Fibrosis
LPA1 (LPAR1) signaling promotes fibroblast recruitment, proliferation, and collagen deposition, contributing to pulmonary fibrosis. Pharmacological inhibition of LPA1 with BMS-986278 reduces fibrosis in preclinical models and is being evaluated in clinical trials [1,2]. Genetic ablation of LPA1 also attenuates fibrosis, validating the receptor as a therapeutic target.
Hypertrophic Cardiomyopathy
LPA1 activation contributes to cardiac hypertrophy and fibrosis. In a mouse model, ablation of LPA1 attenuated hypertrophic cardiomyopathy, suggesting that LPA1 antagonists could be beneficial for this condition.
Neuropathic Pain
LPA5 (LPAR5) in the insular cortex plays a role in neuropathic pain. Targeting LPA5 with antagonists or genetic knockdown may provide analgesia, as demonstrated in preclinical studies. Crosstalk between cannabinoid receptor 2 and LPA5 further modulates pain signaling.
Nonalcoholic Steatohepatitis (NASH)
LPA1 antagonism with EPGN2154 causes regression of NASH in preclinical models, reducing steatosis, inflammation, and fibrosis. This highlights LPA1 as a promising target for metabolic liver disease.
From lysophosphatidic acid receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does LPA1 mediate fibrosis? | Lpar1 knockout mouse; LPA1 antagonist in bleomycin-induced fibrosis model [1,2] |
| What is the role of LPA3 in ferroptosis? | Lpar3 knockout and overexpression cell lines treated with ferroptosis inducers |
| Does LPA5 in insular cortex modulate pain? | Conditional Lpar5 knockout in insular cortex; LPA5 antagonist injection |
| Can LPA1 inhibition reverse NASH? | Lpar1 knockout mouse; EPGN2154 treatment in diet-induced NASH model |
| What is the crosstalk between CB2 and LPA5? | Double knockout or knockdown of Cnr2 and Lpar5 in cell lines |
| Does LPA1 ablation attenuate hypertrophic cardiomyopathy? | Lpar1 knockout mouse in transverse aortic constriction model |
How to Study the lysophosphatidic acid receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR-Cas9 knockout | Loss of receptor function | Validate target in disease models |
| GTPγS binding | G-protein activation | Measure receptor agonist activity |
| cAMP assay | Gi-mediated inhibition of adenylyl cyclase | Assess receptor coupling to Gi |
| Calcium mobilization | Gq-mediated calcium release | Detect receptor activation |
| Western blot | Phosphorylation of downstream effectors (AKT, MAPK) | Monitor signaling pathway activation |
| RNA-seq | Transcriptional changes | Identify LPA receptor expression and downstream targets |
| Immunohistochemistry | Receptor localization in tissues | Study tissue distribution in disease |
| Beta-arrestin recruitment | Receptor desensitization | Measure receptor internalization |
CRISPR-Cas9 Knockout
CRISPR-Cas9 knockout of LPA receptor genes (e.g., LPAR1, LPAR3, LPAR5) in cell lines or animal models enables loss-of-function studies to determine their role in LPA signaling and disease. For example, Lpar1 knockout mice have been used to demonstrate its role in hypertrophic cardiomyopathy.
Pharmacological Modulation
Selective antagonists (e.g., BMS-986278 for LPA1) and agonists are used to probe receptor function. These compounds can be tested in combination with genetic models to validate target engagement and specificity [2,8].
Signaling Assays
LPA-induced G-protein activation can be measured by GTPγS binding, cAMP inhibition, calcium mobilization, or Rho activation assays. Downstream phosphorylation of AKT and MAPK can be assessed by Western blotting.
Gene Expression Analysis
RNA-seq and qPCR can quantify LPA receptor expression levels in tissues or cells under different conditions. This helps identify which receptor subtypes are relevant in a given disease context.
How CRISPR Can Be Used to Study GO:0070915 lysophosphatidic acid receptor activity
Knockout
CRISPR-Cas9 knockout of LPA receptor genes (e.g., LPAR1, LPAR3, LPAR5) creates loss-of-function models to study their contribution to LPA signaling and disease. For instance, Lpar1 knockout mice have been used to demonstrate its role in hypertrophic cardiomyopathy.
Point Mutation
Introducing point mutations in LPA receptor genes can mimic naturally occurring variants or disrupt specific signaling motifs (e.g., phosphorylation sites) to dissect receptor function. This approach helps identify residues critical for G-protein coupling or ligand binding.
Knock-in
Knock-in of tagged LPA receptors (e.g., HA or GFP) allows visualization and biochemical isolation of the receptor. Knock-in of human LPA receptor orthologs into mouse models can humanize the target for drug testing.
Overexpression
Overexpression of LPA receptors in cell lines (e.g., HEK293) via CRISPR activation or lentiviral delivery enhances signaling and enables detailed pharmacological profiling. This is useful for screening antagonists and studying downstream pathways.
How EDITGENE Supports lysophosphatidic acid receptor activity Research
Researchers studying lysophosphatidic acid receptor activity-related genes often need to determine whether a candidate gene is causally involved in a specific signaling pathway or disease phenotype. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such functional studies with high precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for lysophosphatidic acid receptor activity research.
Frequently Asked Questions About lysophosphatidic acid receptor activity
What is lysophosphatidic acid receptor activity?
It is the molecular function defined by GO:0070915, where a receptor binds lysophosphatidic acid (LPA) and activates an associated G-protein to transmit a signal across the membrane.
What genes are involved in lysophosphatidic acid receptor activity?
The main genes are LPAR1, LPAR2, LPAR3, LPAR4, LPAR5, and LPAR6, which encode the six known LPA receptors.
Which diseases are associated with LPA receptors?
LPA receptors are implicated in pulmonary fibrosis, hypertrophic cardiomyopathy, neuropathic pain, NASH, and ferroptosis-related conditions [1,2,4,5,6,8].
How can I study LPA receptor function using CRISPR?
CRISPR-Cas9 knockout, point mutation, knock-in, and overexpression models allow precise manipulation of LPA receptor genes in cells and animals.
What is the role of LPA1 in fibrosis?
LPA1 promotes fibroblast recruitment and collagen deposition; its inhibition reduces fibrosis in preclinical models [1,2].
Is LPA5 a target for pain treatment?
Yes, LPA5 in the insular cortex is a potential analgesic target for neuropathic pain.
What are the signaling pathways downstream of LPA receptors?
LPA receptors couple to G12/13, Gi, Gq, and Gs, activating RhoA, PLC, PI3K/AKT, and MAPK pathways.
Can LPA receptors be targeted by drugs?
Yes, antagonists such as BMS-986278 for LPA1 are in clinical development for fibrosis, and EPGN2154 for NASH [2,8].
What is the link between LPA3 and ferroptosis?
LPA3 activation is involved in the regulation of ferroptosis, a form of regulated cell death.
How does LPA receptor signaling crosstalk with cannabinoid receptors?
Cannabinoid receptor 2 and LPA5 exhibit crosstalk, modulating each other's signaling.
Conclusion
GO:0070915, lysophosphatidic acid receptor activity, represents a critical molecular function that translates the extracellular lipid signal LPA into diverse cellular responses. The six LPA receptors (LPA1–LPA6) are GPCRs with distinct signaling properties and tissue distributions, and their dysregulation is linked to fibrosis, cardiovascular disease, pain, and metabolic disorders. CRISPR-based genome editing provides powerful tools to dissect the specific roles of each receptor and validate them as therapeutic targets. EDITGENE offers comprehensive services to support such research, from knockout and point mutation models to library screening and bioinformatics.
References
- 1. Volkmann ER et al.. 2024. Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosis.. Eur Respir Rev 33(172) PMID: 39009409
- 2. Cheng PTW et al.. 2021. Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA(1)) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases.. J Med Chem 64(21):15549-15581 PMID: 34709814
- 3. Song E et al.. 2023. Crosstalk between cannabinoid receptor 2 and lysophosphatidic acid receptor 5.. Biochem Biophys Res Commun 666:154-161 PMID: 37187093
- 4. Huang YX et al.. 2024. Lysophosphatidic Acid Receptor 3 Activation Is Involved in the Regulation of Ferroptosis.. Int J Mol Sci 25(4) PMID: 38397002
- 5. Axelsson Raja A et al.. 2022. Ablation of lysophosphatidic acid receptor 1 attenuates hypertrophic cardiomyopathy in a mouse model.. Proc Natl Acad Sci U S A 119(28):e2204174119 PMID: 35787042
- 6. Wang B et al.. 2025. Lysophosphatidic acid receptor 5 in insular cortex as a potential analgesic target in neuropathic pain.. Neurotherapeutics 22(5):e00609 PMID: 40393883
- 7. Meduri B et al.. 2021. Lysophosphatidic acid (LPA) receptor modulators: Structural features and recent development.. Eur J Med Chem 222:113574 PMID: 34126459
- 8. Bhattacharjee J et al.. 2023. Lysophosphatidic acid receptor 1 antagonist (EPGN2154) causes regression of NASH in preclinical NASH models.. Hepatol Commun 7(12) PMID: 37994050
